Anavex Life Sciences Corp..
AVXL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Anavex Life Sciences Corp. is a biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system disorders....Show More
Better Health for All
-40
The company's lead drug candidate, blarcamesine, has shown mixed results. While a Phase IIb/III trial for Alzheimer's disease demonstrated clinically meaningful improvement over 48 weeks, slowing clinical progression by 36.3% (and 49.8% in a prespecified group) and brain volume loss,
1
late-stage clinical trials for Rett syndrome and earlier studies for Alzheimer's and Parkinson's disease have failed, with the drug described as a 'zero' in clinical development.
2
The drug has a consistent safety profile with no associated neuroimaging adverse events or deaths related to the study drug, and does not require routine MRI monitoring.
3
The company's operations and clinical programs are estimated to be funded for over 3 years, with $39.0 million in cash utilization for fiscal year 2025 and $35.7 million in R&D expenses for fiscal year 2024.
4
Blarcamesine is an oral small-molecule therapy, which offers health benefits at significantly lower cost compared to biologics.
5
However, the company took seven months to acknowledge the failure of a late-stage clinical trial in Rett syndrome and is described as a 'serial dissembler of clinical trial results.'
6
Compassionate Use Programs for pediatric Rett syndrome patients have high enrollment rates, with 93% of patients completing the open-label extension joining the program.
7
The company has a preclinical stage drug for depression and a Phase 2 clinical trial for schizophrenia.
8
The company has broad IP protection in key markets for product candidates up to 2040.
9
The company's code of conduct mentions compliance with human subject protection in clinical trials and data protection and privacy laws.
10
Fair Money & Economic Opportunity
0
No evidence available to assess Anavex Life Sciences Corp. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
-10
The company's employee rating is 0 out of 100.
1
For 2024, the CEO to median employee pay ratio was 9:1, with the CEO's total compensation at $2,792,669 and the median employee pay at $324,729.
2
Fair Trade & Ethical Sourcing
0
The provided articles, which include privacy policies and a Code of Conduct, do not contain any specific quantitative data or factual information relevant to fair trade and ethical sourcing practices.
1
There is no evidence regarding the percentage of fair-trade certified spend, supplier audit frequency, substantiated forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or procurement budget directed to diverse suppliers.
2
Honest & Fair Business
-40
Anavex Life Sciences Corp. has a formal whistleblower policy that requires reporting of violations and potential violations, along with annual compliance certification.
1
The company also has an anti-corruption policy that prohibits gifts, payments, and conflicts of interest with competitors, customers, or suppliers.
2
However, the articles do not provide details on the frequency or effectiveness of training for this policy, nor do they specify clear guidance on facilitation payments or gift thresholds. Multiple articles mention that securities fraud complaints have been filed against Anavex, alleging false or misleading statements regarding its research program and the likelihood of success for its blarcamesine treatment, but these are allegations and investigations, not regulatory fines.
3
Kind to Animals
0
No evidence available to assess Anavex Life Sciences Corp. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Anavex Life Sciences Corp. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Anavex Life Sciences Corp. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Anavex Life Sciences Corp. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Anavex Life Sciences Corp. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points related to waste management, product sustainability, or circular economy practices were found in the provided articles for Anavex Life Sciences Corp. The articles primarily focus on the company's research and development of treatments for CNS conditions
1
or general ESG risk ratings
2
without detailing specific environmental performance metrics relevant to Zero Waste & Sustainable Products.